# Cannabis Use in Substance Exposed Pregnancy and Postpartum Depression Risk > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ced-cannabis-use-in-substance-exposed-p-2026-10-04/ > **Published:** 2026-10-04T09:38:11-04:00 | **Last Modified / Clinically Audited:** 2026-10-04T09:38:11-04:00 > **Clinical Summary:** medical cannabis research: Physician review of Postpartum Depression Following a Substance-Exposed Pregnancy: The Role of Age, Race/Ethnicity, and Mental Hea... --- CED Clinical Relevance #88 Verified Clinical Evidence Primary literature analysis of Postpartum Depression Following a Substance-Exposed Pregnancy: The Role of Age, Race/Ethnicity, and Mental Health History.. Clinical Insight | CED Clinic This chart review highlights a difficult clinical intersection: prenatal substance exposure, postpartum depression screening, race, insurance status, and cannabis use. Among 255 mother infant dyads with biochemically confirmed prenatal substance use, 30.19% met criteria for postpartum depression through six months, based mainly on Edinburgh Postnatal Depression Scale scores of 10 or higher or documented diagnosis or treatment. Marijuana use had the strongest reported association, with adjusted odds of PPD about 3.4 times higher. Clinically, this should not be read as proof that cannabis causes postpartum depression. It does support more proactive, nonpunitive screening for mood symptoms among pregnant and postpartum patients reporting cannabis or other substance use. Clinical SciencePeer-ReviewedDosing ContextSafety SignalsPhysician Insight AudiencePatients, clinicians, healthcare providers, researchers, and policy analysts. Primary TopicClinical study review: Cannabis Use in Substance Exposed Pregnancy and Po. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42828393/) Table of Contents - [Cannabis Use in Substance Exposed Pregnancy and Postpartum Depression Risk](#Cannabis_Use_in_Substance_Exposed_Pregnancy_and_Postpartum_Depression_Risk)[How to Interpret This Clinical Study](#How_to_Interpret_This_Clinical_Study)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Clinical Viewpoints](#CED_Perspective_Lens_Eight_Clinical_Viewpoints)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis) - [Patient Communication](#Patient_Communication) - [Dosing & Formulations](#Dosing_Formulations) - [Safety & Side Effect Profile](#Safety_Side_Effect_Profile) - [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics) - [Mechanisms & Physiology](#Mechanisms_Physiology) - [Research Limitations](#Research_Limitations) - [Future Outlook](#Future_Outlook) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # Cannabis Use in Substance Exposed Pregnancy and Postpartum Depression Risk In 255 substance exposed pregnancies, postpartum depression affected 30.19%. Prenatal marijuana use, Black or mixed race identity, and private insurance status were associated with higher documented PPD risk. What This Study Teaches Us In 255 pregnancies with biochemically confirmed prenatal substance exposure, 30.19% developed postpartum depression through six months postpartum. Marijuana use was associated with higher odds of PPD, OR 3.4, 95% CI 1.66 to 6.96, while private insurance was associated with OR 1.96, 95% CI 1.09 to 4.28, and age plus prior mental health history were not significant in adjusted analysis. Why This Matters For patient care, prenatal cannabis use in a substance exposed pregnancy may help identify patients who need earlier postpartum mood screening, warmer handoffs, and lower barriers to treatment. The findings also warn clinicians not to oversimplify PPD risk, because race, insurance, documentation patterns, and care access may shape who is identified. Study SnapshotPost TypePhysician-Guided Clinical Science Deep DivePrimary SourceCureusPublication Date2026SepEvidence LevelJournal ArticleFocus AreaCannabis Use in Substance Exposed Pregnancy and Postpartum DLead AuthorsNatalie Aguilar, Miranda C Manzo, Patrick Fakhoury, Jacob SurmaDOI10.7759/cureus.115659PMIDPMID: 42828393 Clinical Bottom Line This study review translates complex data into practical clinical insights, maintaining realistic therapeutic expectations. Headline vs. Reality Truth Meter | Clinical Analysis **Mainstream Media Claim:** Cannabis use during pregnancy causes postpartum depression and should be treated as the primary explanation for later maternal mood symptoms. **Primary Journal Data:** In a retrospective chart review of 255 substance exposed pregnancies, 30.19% had PPD. Marijuana use was associated with higher odds of PPD, OR 3.4, 95% CI 1.66 to 6.96. Private insurance was also associated with higher odds, OR 1.96, 95% CI 1.09 to 4.28, and race or ethnicity showed elevated risk patterns. Age and prior mental health history were not significant in the adjusted model. **Dr. Caplan’s Clinical Verdict:** The study identifies cannabis exposure as a clinically important risk marker within an already high risk cohort, not as a proven causal agent. The safer interpretation is targeted depression screening, respectful substance use history taking, and careful follow up rather than stigma or automatic blame. Primary Analysis | Postpartum Depression Following a Substa **Study Overview:** Background and objective Postpartum depression (PPD) affects 13-19% of postpartum individuals and is one of the most prevalent complications of pregnancy, with significant consequences for maternal and child well-being. Research suggests that maternal age, ethnic minority status, and a history of depression are predictors of PPD. Nearly one-third of substance users also experience PPD, yet it is unclear how age, race/ethnicity, and mental health history predict PPD in this already at-risk population. This study aimed to examine the impact of age, race/ethnicity, and depression history on the development of PPD among individuals who used substances during pregnancy. Methods A medical chart review was conducted at two university-affiliated pediatric practices in the Midwestern United States. Eligible participants were those with available maternal prenatal and delivery records, pediatric medical records through age three years, and biochemically confirmed prenatal substance use. The primary outcome was PPD, assessed primarily using the Edinburgh Postnatal Depression Scale with a score ≥ 10 through six months postpartum and/or a documented maternal report of a postpartum depression diagnosis or treatment. Results Of 255 participants, 30.19% experienced PPD. Private medical insurance holders (a proxy for higher socioeconomic status (SES)) were twice as likely to develop PPD (odds ratio (OR) = 1.96, 95% confidence interval (CI): 1.09-4.28), while marijuana use increased the risk by nearly 3.4-fold (OR = 3.4, 95% CI: 1.66-6.96). Black women were nearly two and a half times more likely than White, non-Hispanic women to develop PPD, and women who reported another race or mixed race were more than four times more likely to develop PPD. A history of mental health conditions predicted a non-significant, fourfold increase in PPD risk. Age was not a significant predictor. Marijuana use and higher SES were the strongest predictors of PPD in this substance-exposed population. Conclusions Marijuana use during pregnancy, race/ethnicity, and private insurance status were independent predictors of PPD in this substance-exposed cohort. Age and pre-pregnancy mental health history were not significant in the adjusted analysis. These findings highlight the need for targeted maternal mental health screening and further research on ascertainment differences by SES. **Primary Source & Scope:** Published in *Cureus* (2026Sep) conducted by Natalie Aguilar, Miranda C Manzo, Patrick Fakhoury, Jacob Surma. [Primary Source Link](https://pubmed.ncbi.nlm.nih.gov/42828393/) | **Primary Record:** DOI: 10.7759/cureus.115659 | PMID: 42828393 How Strong Is This Evidence? The study uses a clinically relevant retrospective chart review across two university affiliated pediatric practices, with 255 eligible participants and biochemically confirmed prenatal substance use. The outcome definition captured both screening results and documented diagnosis or treatment through six months postpartum, which improves pragmatic sensitivity. Adjusted odds ratios and confidence intervals were reported for key predictors, supporting a quantitative assessment of association. Where This Paper Deserves Skepticism Retrospective chart review designs depend heavily on documentation quality, screening frequency, and care access, all of which can differ by insurance, race, clinic engagement, and clinician behavior. Cannabis use may be confounded by psychiatric symptoms before pregnancy, nausea severity, trauma exposure, polysubstance use intensity, social stress, and reasons for use. The non significant fourfold signal for prior mental health conditions suggests possible limited power, missing data, or measurement imprecision. What This Paper Does Not Show This study does not prove that cannabis biologically causes postpartum depression or that stopping cannabis during pregnancy would reduce PPD risk by a specific amount. It also does not establish a safe prenatal cannabis dose, product type, THC threshold, or regulatory rule for pregnancy care. How This Fits With the Broader Clinical Conversation Clinical research into Postpartum Depression Following a Substance-Expose is progressing through rigorously documented peer-reviewed cohorts. Evaluating primary evidence enables clinicians to tailor care plans while respecting therapeutic boundaries. Editorial Commentary *From a clinical perspective, Postpartum Depression Following a Substance-Exposed Pregnancy: The Role of Age, Race/Ethnicity, and Mental Health History. underscores the necessity of evaluating primary data rather than commercial headlines.* *Clinicians discussing these findings should ground patient recommendations in individualized care, verified formulation standards, and monitored therapeutic outcomes.* What a Careful Reader Should Take Away Prenatal cannabis use in a substance exposed pregnancy should trigger supportive postpartum depression screening, not stigma. Clinicians should ask why the patient used cannabis, assess mood and safety repeatedly, and coordinate behavioral health care early. [https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about this study:[🤰Pregnancy](https://cedclinic.com/ask)[🧠Anxiety and Mood](https://cedclinic.com/ask)[🧸Children and Teens](https://cedclinic.com/ask)[🔎This study's limits](https://cedclinic.com/ask) Evidence Interpretation Guide ## How to Interpret This Clinical Study Navigating biomedical publications regarding Postpartum Depression Following a Substance-E requires reviewing study methodology and patient eligibility. ### Three Rules for Critical Reading **Critical Rule**Separate association from causation, because this retrospective chart review can identify risk markers but cannot prove marijuana caused postpartum depression. **Critical Rule**Treat private insurance and race findings as potentially influenced by ascertainment, access, structural inequity, documentation quality, and differential screening. **Critical Rule**Do not infer dosing, THC potency, CBD effects, route specific risk, or medical cannabis guidance, since exposure detail was not reported. Key Evaluation Question Were marijuana use and insurance status true biologic or social risk factors, or did they partly identify patients more likely to be screened, diagnosed, and documented? The Patient Question Given my cannabis or substance use history, how often should I be screened for postpartum depression, and what support is available without judgment? The Bottom Line In substance exposed pregnancies, prenatal marijuana use was associated with higher documented postpartum depression risk, but the finding should drive compassionate screening and support rather than causal certainty or stigma. CED Perspective Lens ## CED Perspective Lens: Eight Clinical Viewpoints Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives Lens OverviewEight structured clinical perspectives synthesizing primary study data for patient care. #### Clinical Evidence Synthesis This retrospective chart review examined 255 pregnancies with biochemically confirmed prenatal substance exposure and pediatric follow up through age three. Postpartum depression was identified through six months using Edinburgh Postnatal Depression Scale scores of 10 or higher, documented diagnosis, or documented treatment. PPD occurred in 30.19% of the cohort. Marijuana use was associated with substantially higher adjusted odds, OR 3.4, 95% CI 1.66 to 6.96. Private insurance, a proxy for higher socioeconomic status or better ascertainment, was also associated with higher odds. Lens takeawayThe study supports cannabis exposure as a risk marker, not a standalone causal explanation. #### Patient Communication Patients who used substances during pregnancy may already fear judgment, surveillance, or custody consequences. A cannabis disclosure should be treated as clinically useful information, not a reason for shaming or withdrawal of care. The practical response is repeated depression screening, direct questions about sleep, anxiety, intrusive thoughts, bonding, safety, and support. Clinicians should explain that cannabis use may signal higher PPD risk while also asking what symptoms the patient was trying to manage. Open and transparent discussions with healthcare providers help clarify realistic treatment timelines, administration methods, and appropriate product selection. Lens takeawayBetter outcomes start with nonpunitive questions that keep patients engaged in care. #### Dosing & Formulations This study does not report THC dose, CBD content, product type, frequency, route, timing, or potency. Therefore, it cannot compare smoked cannabis, vaping, edibles, concentrates, tinctures, or medical versus nonmedical use. For clinical counseling, the absence of dose detail matters. A positive marijuana exposure variable cannot guide cannabinoid ratios, taper schedules, or harm reduction product choices during pregnancy or postpartum. Individualized dose titration, documented cannabinoid ratios, and monitored therapeutic responses remain essential for maximizing clinical benefit while minimizing adverse side effects. Lens takeawayNo dosing conclusion can be drawn from an exposure variable without product detail. #### Safety & Side Effect Profile The safety signal here is maternal mental health risk after a substance exposed pregnancy. PPD is not a minor outcome, since it can affect sleep, bonding, breastfeeding, relationship stress, infant care, and crisis risk. Cannabis may be used to manage nausea, insomnia, appetite, pain, or anxiety, but those same symptoms can overlap with mood vulnerability. Screening should include suicidality, psychosis symptoms, intimate partner violence, and polysubstance exposure. Ongoing post-market surveillance, contaminant screening, and standardized adverse-event reporting remain critical safeguards for patient health. Lens takeawayCannabis history should open a wider safety assessment, not close the conversation. #### Regulatory & Policy Dynamics Pregnancy substance policies can unintentionally reduce disclosure if patients fear punishment. This study argues for targeted postpartum screening, but it does not justify punitive surveillance or automatic reporting based only on cannabis exposure. The private insurance association is a policy warning. Higher documented PPD may reflect better access, more screening, or more complete records rather than truly higher biologic risk among privately insured patients. Consistent administrative oversight and clear statutory definitions ensure that public health protections keep pace with evolving consumer formulations. Lens takeawayPolicy should increase supportive screening access without making disclosure more dangerous. #### Mechanisms & Physiology Potential biologic pathways could involve endocannabinoid signaling, stress responsivity, sleep regulation, reward circuitry, inflammation, and hormonal transitions after delivery. These mechanisms are plausible but were not directly measured in this chart review. Equally plausible are nonbiologic pathways, including self treatment of preexisting distress, trauma burden, socioeconomic strain, stigma, or differences in clinical detection. The observed association may combine several pathways. Investigating receptor affinities, pharmacokinetic pathways, and cellular interactions clarifies the biological mechanisms underlying observed clinical outcomes. Lens takeawayMechanistic hypotheses remain plausible, but this paper measured association rather than biology. #### Research Limitations The study was retrospective and based on two pediatric practices in the Midwestern United States, which limits generalizability. Documentation gaps may have affected both exposure classification and postpartum depression identification. Important variables were likely incomplete or unmeasured, including cannabis dose, timing, frequency, product potency, indication for use, psychiatric symptom severity, trauma history, social support, and detailed polysubstance patterns. Readers should carefully evaluate cohort composition, potential confounding variables, and study duration before generalizing preliminary findings across broader clinical populations. Lens takeawayThe findings are clinically useful, but confounding and documentation bias remain central concerns. #### Future Outlook Future studies should prospectively follow pregnant patients with standardized mood assessments before pregnancy, during pregnancy, and after birth. Cannabis exposure should be measured by timing, frequency, route, potency, and reason for use. The next research step is to separate pharmacologic cannabis effects from self treatment and structural risk. Trials of integrated postpartum behavioral health for substance exposed pregnancies may be more immediately actionable than exposure studies alone. Future prospective investigations with standardized formulations and long-term follow-up will provide critical clarity as clinical evidence matures. Lens takeawayProspective, detailed exposure research is needed alongside better postpartum support systems. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Cannabis+Use+in+Substance+Exposed+Pregnancy+and+Postpartum+Depression+Risk&url=https%3A%2F%2Fcedclinic.com%2Fced-cannabis-use-in-substance-exposed-p-2026-10-04%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-cannabis-use-in-substance-exposed-p-2026-10-04%2F) [BlueSky](https://bsky.app/intent/compose?text=Cannabis+Use+in+Substance+Exposed+Pregnancy+and+Postpartum+Depression+Risk%20https%3A%2F%2Fcedclinic.com%2Fced-cannabis-use-in-substance-exposed-p-2026-10-04%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Source: Postpartum Depression Following a Substance-Exposed Pregnancy: The Role of Age, Race/Ethnicity, and Mental Health History.](https://pubmed.ncbi.nlm.nih.gov/42828393/) Related Reading at CED ClinicContinue exploring the evidence[Prenatal Cannabis Use and Motivation to Quit: What a New Study Found](https://cedclinic.com/prenatal-cannabis-quit-motivation-study/) More on this topic: Dr. Caplan evaluates pregnant patients’ motivation to stop or reduce cannabis use, clinical cessation discussions, and quitline uptake barriers. [More on this topic: Prenatal quit motivation](https://cedclinic.com/prenatal-cannabis-quit-motivation-study/)[Prenatal Cannabis Exposure and Neurodevelopment: What the New Systematic Review Actually Shows](https://cedclinic.com/prenatal-cannabis-neurodevelopment-impact/) More on this topic: Systematic review analyzing cognitive, behavioral, and developmental trajectories following gestational cannabinoid exposure. [More on this topic: Fetal neurodevelopment](https://cedclinic.com/prenatal-cannabis-neurodevelopment-impact/)[Medical Cannabis During Pregnancy and Breastfeeding: Is the Concern Fully Evidence-Based?](https://cedclinic.com/medical-cannabis-during-pregnancy-and-breastfeeding-is-the-concern-fully-evidence-based/) More on this topic: Critical evaluation of placental cannabinoid transfer, neonatal data, and clinical counseling during lactation. [More on this topic: Pregnancy & breastfeeding](https://cedclinic.com/medical-cannabis-during-pregnancy-and-breastfeeding-is-the-concern-fully-evidence-based/) ## Frequently Asked Questions Did this study prove that cannabis causes postpartum depression? No. It found an association between prenatal marijuana use and higher documented odds of postpartum depression in a substance exposed cohort. Retrospective observational data cannot prove causation. How common was postpartum depression in this study? Postpartum depression was identified in 30.19% of 255 participants, using Edinburgh Postnatal Depression Scale scores of 10 or higher through six months postpartum and/or documented diagnosis or treatment. How strong was the marijuana association? Marijuana use was associated with about 3.4 times higher adjusted odds of postpartum depression, with a 95% confidence interval of 1.66 to 6.96. Does this mean cannabis should be used to screen people out of care? No. The clinical use of this finding is supportive screening and follow up, not exclusion, punishment, or stigmatizing treatment. Why might private insurance be linked with higher PPD documentation? Private insurance may reflect socioeconomic differences, but it may also reflect better access to screening, diagnosis, treatment, and more complete medical documentation. Was age a predictor of postpartum depression? No. Age was not a significant predictor of postpartum depression in the adjusted analysis reported in the study summary. Was prior mental health history a significant predictor? No. Prior mental health history showed a non significant roughly fourfold increase in risk, meaning the estimate suggested possible risk but lacked statistical certainty in this analysis. How should clinicians discuss cannabis use during pregnancy? Clinicians should ask nonjudgmentally about reason for use, frequency, route, product type, THC content if known, coexisting symptoms, and whether the patient feels able to reduce use with support. Does this study provide [cannabis dosing](https://cedclinic.com/cbd-gummies-and-psychosis-evidence-review/) guidance for pregnancy or postpartum? No. The study did not report dose, THC or CBD content, route, timing, or product type, so it cannot guide dosing, ratios, or formulation choices. What should a postpartum patient do if they used cannabis during pregnancy and feel depressed? They should contact an obstetric, primary care, pediatric, or mental health clinician promptly for depression screening, safety assessment, and treatment options. Urgent help is needed for suicidal thoughts, thoughts of harming the baby, hallucinations, or feeling unsafe. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).